NFKB1 and hepatocellular carcinoma: In human hepatocellular carcinoma cells, diosgenin inhibits NF-κB activity and the activation of NF-κB/STAT3, leading to a significant decrease in the expression of various oncogene products and the inhibition of cell proliferation [85].